Key Highlights

• Avecho has recommenced recruitment for the second and final cohort of its pivotal Phase III insomnia trial.

• The independent Data Monitoring Board recommended continuing to the planned total enrolment of 519 participants.

• Approximately 320 additional participants are targeted for the final cohort through the company's clinical-site network.

• AVE is trading at AUD 0.022, up 15.79% during Tuesday's session.

Avecho Biotechnology (ASX:AVE) is trading at AUD 0.022 during Tuesday's session, up 15.79%, as its lead clinical program moves deeper into the final stage of a pivotal Phase III insomnia trial. The company recommenced recruitment at the end of August after an independent interim review recommended that the study continue to its originally planned enrolment of 519 participants. The trial remains blinded and ongoing, making completion of recruitment, dosing and final analysis the central milestones ahead.

Final Cohort Recruitment Restarts

Avecho announced on 31 August that recruitment had recommenced for the second and final patient cohort of its Phase III study evaluating a TPM-enhanced cannabidiol soft-gel capsule for insomnia. Approximately 320 additional participants are planned for this cohort. Recruitment is taking place through Avecho's existing clinical-site network, with additional sites being activated progressively. This phase follows completion of the interim cohort and moves the study towards the total planned enrolment of 519 participants.

Interim Review Supports the Original Trial Size

The restart follows the interim analysis announced in June. An independent Data Monitoring Board reviewed unblinded interim data and unanimously recommended that the trial continue to its originally planned enrolment. The study therefore did not require an increase in the planned sample size. Safety formed part of the interim review, and Avecho reported that no serious adverse events had been identified among the 244 participants assessed at that stage. The company has also made clear that the study remains blinded and that final outcomes cannot be determined until the trial is completed.

Company Introduction and TPM Platform

Avecho is a biotechnology company developing products using its proprietary TPM drug-delivery platform. TPM is based on tocopheryl phosphate, a modified form of vitamin E, and is used by the company to develop formulations intended to improve the delivery, effectiveness or tolerability of established active ingredients. Avecho's current lead program is an oral CBD soft-gel capsule for insomnia. The company has also worked on topical and other formulations and has existing commercialised TPM products under licence.

Sandoz Partnership Provides an Australian Commercial Route

Avecho has an Australian licensing and development agreement with Sandoz for the CBD insomnia capsule. Under the agreement announced in 2025, Sandoz received exclusive Australian commercialisation rights, while Avecho retained responsibility for Manufacturing and Supply through third-party contract manufacturers. The arrangement includes an upfront payment, potential development milestones and tiered royalties on net sales. This means the clinical program is progressing alongside an established commercial framework for Australia, although regulatory approval and successful completion of development remain necessary before commercialisation.

Sector Context

Avecho operates within biotechnology and pharmaceutical development, where late-stage Clinical Trials are designed to provide evidence required for regulatory submissions. Phase III studies involve larger patient populations and are intended to evaluate efficacy and safety under a defined protocol. Avecho's trial is assessing its CBD formulation specifically for insomnia. While the positive interim recommendation allowed the program to continue without increasing enrolment, it does not establish the final efficacy outcome. The final dataset will therefore be important for the company's regulatory and commercial plans.

Risks to Consider

Clinical development carries material uncertainty. The final Phase III results may differ from indications observed at an interim stage, and the study remains blinded. Recruitment timelines can also change depending on site activation and patient enrolment. Even if the trial meets its endpoints, regulatory review is required before the product can be registered and commercialised. Manufacturing scale-up, stability work, partner execution and funding are additional considerations. Avecho has been preparing manufacturing activities in parallel, but successful development still depends on several clinical and regulatory steps.

Things to Watch Next

The immediate focus is recruitment and dosing of the final cohort, followed by completion of the Phase III study and release of final results. Investors will also be watching regulatory preparation, manufacturing readiness and any licensing activity outside Australia. The existing Sandoz arrangement provides a defined Australian commercial partner, while other territories remain relevant to Avecho's broader strategy. AVE is trading at AUD 0.022, up 15.79% during Tuesday's session. The stock has gained 175% over one year, keeping execution of the final trial stage firmly in focus.

Summary

Avecho's next milestones are completion of final-cohort recruitment, Phase III read-out and regulatory preparation, while manufacturing readiness and licensing activity will shape the commercial pathway beyond the trial.